Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition.
Reginelli
Joel P
JP
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave., Desk F25, Cleveland, OH 44195, USA. reginej@ccf.org
Chew
Derek
D
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods; D001120:Arginine / Q000031:analogs & derivatives; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives*; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use; D010875:Pipecolic Acids / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013449:Sulfonamides
D005343:Fibrinolytic Agents; D006629:Hirudins; D010446:Peptide Fragments; D010875:Pipecolic Acids; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D013449:Sulfonamides; D001120:Arginine; C031942:argatroban; C074619:bivalirudin